XML 109 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)
12 Months Ended
Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]  
Schedule of Quarterly Financial Information [Table Text Block]
SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
Dollars in Millions, except per share data
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Year
2013
 
 
 
 
 
 
 
 
 
 
Total Revenues
 
$
3,831

 
$
4,048

 
$
4,065

 
$
4,441

 
$
16,385

Gross Margin
 
2,768

 
2,940

 
2,890

 
3,168

 
11,766

Net Earnings
 
623

 
530

 
692

 
735

 
2,580

Net Earnings/(Loss) Attributable to:
 
 
 
 
 
 
 
 
 
 
Noncontrolling Interest
 
14

 
(6
)
 

 
9

 
17

BMS
 
609

 
536

 
692

 
726

 
2,563

 
 
 
 
 
 
 
 
 
 
 
Earnings per Share - Basic(1)
 
$
0.37

 
$
0.33

 
$
0.42

 
$
0.44

 
$
1.56

Earnings per Share - Diluted(1)
 
0.37

 
0.32

 
0.42

 
0.44

 
1.54

 
 
 
 
 
 
 
 
 
 
 
Cash dividends declared per common share
 
$
0.35

 
$
0.35

 
$
0.35

 
$
0.36

 
$
1.41

 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
1,355

 
$
1,821

 
$
1,771

 
$
3,586

 
$
3,586

Marketable securities(2)
 
4,420

 
4,201

 
4,574

 
4,686

 
4,686

Total Assets
 
35,958

 
36,252

 
36,804

 
38,592

 
38,592

Long-term debt(3)
 
7,180

 
7,122

 
6,562

 
7,981

 
7,981

Equity
 
13,699

 
14,373

 
14,714

 
15,236

 
15,236

 
 
 
 
 
 
 
 
 
 
 
Dollars in Millions, except per share data
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
Year
2012
 
 
 
 
 
 
 
 
 
 
Total Revenues
 
$
5,251

 
$
4,443

 
$
3,736

 
$
4,191

 
$
17,621

Gross Margin
 
3,948

 
3,198

 
2,749

 
3,116

 
13,011

Net Earnings/(Loss)
 
1,482

 
808

 
(713
)
 
924

 
2,501

Net Earnings/(Loss) Attributable to:
 
 
 
 
 
 
 
 
 
 
Noncontrolling Interest
 
381

 
163

 
(2
)
 
(1
)
 
541

BMS
 
1,101

 
645

 
(711
)
 
925

 
1,960

 
 
 
 
 
 
 
 
 
 
 
Earnings/(Loss) per Share - Basic(1)
 
$
0.65

 
$
0.38

 
$
(0.43
)
 
$
0.56

 
$
1.17

Earnings/(Loss) per Share - Diluted(1)
 
0.64

 
0.38

 
(0.43
)
 
0.56

 
1.16

 
 
 
 
 
 
 
 
 
 
 
Cash dividends declared per common share
 
$
0.34

 
$
0.34

 
$
0.34

 
$
0.35

 
$
1.37

 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
2,307

 
$
2,801

 
$
1,503

 
$
1,656

 
$
1,656

Marketable securities(2)
 
6,307

 
5,968

 
5,125

 
4,696

 
4,696

Total Assets
 
32,408

 
31,667

 
36,044

 
35,897

 
35,897

Long-term debt(3)
 
5,270

 
5,209

 
7,227

 
7,232

 
7,232

Equity
 
16,246

 
15,812

 
13,900

 
13,638

 
13,638

Selected Quarterly Data Specified Items [Table Text Block]
The following specified items affected the comparability of results in 2013 and 2012:
2013
Dollars in Millions
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Year
Accelerated depreciation, asset impairment and other shutdown costs
 
$

 
$

 
$

 
$
36

 
$
36

Amortization of acquired Amylin intangible assets
 
138

 
137

 
137

 
137

 
549

Amortization of Amylin alliance proceeds
 
(67
)
 
(67
)
 
(68
)
 
(71
)
 
(273
)
Amortization of Amylin inventory adjustment
 
14

 

 

 

 
14

Cost of products sold
 
85

 
70

 
69

 
102

 
326

 
 
 
 
 
 
 
 
 
 
 
Marketing, selling and administrative(a)
 
1

 
1

 
4

 
10

 
16

 
 
 
 
 
 
 
 
 
 
 
Research and development(b)
 

 

 

 
16

 
16

 
 
 
 
 
 
 
 
 
 
 
Provision for restructuring
 
33

 
173

 
6

 
14

 
226

Pension settlements
 

 
99

 
37

 
25

 
161

Acquisition and alliance related items
 

 
(10
)
 

 

 
(10
)
Litigation charges/(recoveries)
 

 
(23
)
 

 

 
(23
)
Upfront, milestone and other licensing receipts
 
(14
)
 



 

 
(14
)
Other (income)/expense
 
19

 
239

 
43

 
39

 
340

 
 
 
 
 
 
 
 
 
 
 
Increase to pretax income
 
105

 
310

 
116

 
167

 
698

Income tax on items above
 
(35
)
 
(116
)
 
(40
)
 
(51
)
 
(242
)
Increase to net earnings
 
$
70

 
$
194

 
$
76

 
$
116

 
$
456

(a)
Specified items in marketing, selling and administrative are process standardization implementation costs.
(b)
Specified items in research and development are upfront, milestone and other licensing payments.
2012
Dollars in Millions
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Year
Accelerated depreciation, asset impairment and other shutdown costs
 
$

 
$
147

 
$

 
$

 
$
147

Amortization of acquired Amylin intangible assets
 

 

 
91

 
138

 
229

Amortization of Amylin alliance proceeds
 

 

 
(46
)
 
(68
)
 
(114
)
Amortization of Amylin inventory adjustment
 

 

 
9

 
14

 
23

Cost of products sold
 

 
147

 
54

 
84

 
285

 
 
 
 
 
 
 
 
 
 
 
Stock compensation from accelerated vesting of Amylin awards
 

 

 
67

 

 
67

Process standardization implementation costs
 
8

 
5

 
3

 
2

 
18

Marketing, selling and administrative
 
8

 
5

 
70

 
2

 
85

 
 
 
 
 
 
 
 
 
 
 
Stock compensation from accelerated vesting of Amylin awards
 

 

 
27

 

 
27

Upfront, milestone and other licensing payments
 

 

 
21

 
26

 
47

IPRD impairment
 
58

 
45

 

 
39

 
142

Research and development
 
58

 
45

 
48

 
65

 
216

 
 
 
 
 
 
 
 
 
 
 
Impairment charge for BMS-986094 intangible asset
 

 

 
1,830

 

 
1,830

 
 
 
 
 
 
 
 
 
 
 
Provision for restructuring
 
22

 
20

 
29

 
103

 
174

Gain on sale of product lines, businesses and assets
 

 

 

 
(51
)
 
(51
)
Pension settlements
 

 

 

 
151

 
151

Acquisition and alliance related items
 
12

 
1

 
29

 
1

 
43

Litigation charges/(recoveries)
 
(172
)
 
22

 
50

 
55

 
(45
)
Upfront, milestone and other licensing receipts
 

 

 

 
(10
)
 
(10
)
Out-licensed intangible asset impairment
 
38

 

 

 

 
38

Loss on debt repurchases
 
19

 

 
8

 

 
27

Other (income)/expense
 
(81
)
 
43

 
116

 
249

 
327

 
 
 
 
 
 
 
 
 
 
 
Increase to pretax income
 
(15
)
 
240

 
2,118

 
400

 
2,743

 
 
 
 
 
 
 
 
 
 
 
Income tax on items above
 
8

 
(77
)
 
(722
)
 
(156
)
 
(947
)
Specified tax benefit(a)
 

 

 

 
(392
)
 
(392
)
Income taxes
 
8

 
(77
)
 
(722
)
 
(548
)
 
(1,339
)
Increase/(Decrease) to Net Earnings
 
$
(7
)
 
$
163

 
$
1,396

 
$
(148
)
 
$
1,404